Table 3 Primary and secondary endpoints for the sacubitril valsartan and control groups
Outcome | SV (n = 59) | Control (n = 59) | P |
|---|---|---|---|
Primary Composite Endpoints | Â | Â | Â |
Total number of hospitalizations for HF and death from cardiovascular causes | 19 | 24 | 0.1 |
Total number of hospitalizations for HF | 17 | 20 | 0.5 |
Death from cardiovascular causes, number (%) | 2 (3.39) | 4 (6.78) | 0.3 |
Secondary endpoints | Â | Â | Â |
Changes in ADQI HF class from baseline to 12 months, number (%) |  |  | Pearson X2 = 24.191 P < 0.001 |
 Improved | 39 (66.10) | 15 (25.42) | -- |
 Unchanged | 19 (32.21) | 33 (55.93) | -- |
 Worsened | 1 (1.69) | 11 (18.64) | -- |
Death from all causes, number (%) | 3 (5.08) | 4 (6.78) | 0.5 |